Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03959293
Title Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Federation Francophone de Cancerologie Digestive

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma


Durvalumab + Fluorouracil + Irinotecan + Leucovorin + Tremelimumab

Durvalumab + Fluorouracil + Irinotecan + Leucovorin

Age Groups: adult | senior
Covered Countries FRA

No variant requirements are available.